Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, and pharmacokinetics (PK) study of a single
dose of 150 mg AT1001 (migalastat HCl, GR181413A) administered orally to healthy subjects
with normal renal function and to subjects with mild, moderate, and severe renal impairment.